『Psychedelic Medicine Podcast with Dr. Lynn Marie Morski』のカバーアート

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

著者: Lynn Marie Morski MD JD
無料で聴く

このコンテンツについて

Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.All podcast episodes and show notes are copyright Lynn Marie Morski, 2025. 心理学 心理学・心の健康 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Is Psilocybin Safe for Me? with Seth Mehr, MD
    2025/07/09

    In this episode, Seth Mehr, MD joins to share his expertise on safety planning prior to a payment undergoing psilocybin therapy. After a 20 year career as an Emergency Medicine physician, Seth founded Cascade Psychedelic Medicine in 2021, treating clients with depression, anxiety and PTSD with psychedelic ketamine therapy. He also serves as the Health & Safety Director and a state licensed psilocybin facilitator at the Innertrek service center in Portland, Oregon.

    In this conversation, Dr. Mehr outlines key risk categories for psilocybin therapy: medical conditions, medication interactions, and mental health history. He emphasizes the importance of individualized safety planning over binary yes/no decisions. Dr. Mehr discusses specific considerations such as cardiovascular issues, diabetes, serotonergic medications, substance use disorders, suicidal ideation, and family history of psychosis. The conversation also covers strategies for mitigating risk, including delaying treatment, contingency plans, improving support systems, and ensuring informed consent. Throughout, Dr. Mehr stresses a collaborative, nuanced approach that balances potential benefits with careful preparation and personalized care.

    In this episode, you'll hear:

    • Stories from Dr. Mehr’s practice of helping patients with different conditions and histories ensure safe psilocybin experiences
    • Interactions between GLP-1 agonists and psilocybin
    • How Dr. Mehr works with patients who have family histories or psychosis
    • Harm reduction practices which leverage other psychedelics or non-psychedelic interventions to help prepare a client for a psilocybin session
    • Why insulin dependent diabetes can be a contraindication for psychedelic therapy
    • What medication combinations can increase the risk of serotonin toxicity with psilocybin
    • Supporting clients experiencing spiritual emergency following psilocybin therapy
    • Safety considerations when working with clients who have a history of seizures
    • The importance of having contingency plans if medical emergencies arise during psilocybin therapy
    • The intricacies of providing fully informed consent for psychedelic therapy

    Quotes:

    “There is some evidence now that taking a single serotonergic agent—say, taking Lexapro—and no other medications that increase the risk of serotonin toxicity seems safe where I am not at this point recommending that people stop, skip, or taper a single SSRI in preparation for a psilocybin session due to safety.” [12:20]

    “One of the difficulties with making these decisions or speaking with some confidence or authority on the matter is that the clinical trials that have been done largely exclude people with lots of conditions—family history and specifically first degree relatives with history of psychosis and bipolar disorder… So we have anecdotal evidence, we have population based surveys to go by. And so when I talk to clients about this, I speak from a place of humility.” [27:30]

    “I always emphasize to clients that while we're talking about a specific safety issue like serotonin toxicity, we don't want to trade that for psychological instability and crisis and declare success because we've helped somebody taper off of a medication that seems less safe and now they aren't sleeping, they're agitated, they're depression is worse, their suicidality is worse. So we have to take a holistic approach to this and consider the totality of what's happening with that client.” [36:45]

    “There are so many different components to trying to set somebody up for success rather than a yes/no, black and white approach [to psilocybin therapy].” [48:44]

    Links:

    Cascade Psychedelic Medicine website

    InnerTrek website

    Managing Medical Risk In Patients Seeking Psilocybin Therapy CME/CE Course

    Psychedelic Medicine Association

    Porangui

    続きを読む 一部表示
    53 分
  • Addressing Racial Trauma through Psychedelic Therapy with Monnica T. Williams, PhD, ABPP
    2025/06/25

    In this episode, Monnica T. Williams, PhD, ABPP joins to discuss how psychedelics may help alleviate mental health impacts of racial trauma. Dr. Williams is a licensed clinical psychologist and professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair in Mental Health Disparities.

    In this conversation, Dr. Williams begins by highlighting the daily stress and trauma experienced by people of color, likening it to PTSD. She discusses a survey her team conducted which revealed that many people of color use psychedelics to manage racial trauma, showing significant reductions in stress, depression, and anxiety. Additionally, Dr. Williams emphasizes the importance of a safe environment and culturally competent therapists. In closing, she discusses ongoing research at this intersection and the need for more funding and awareness in this field.

    In this episode, you'll hear:

    • How racial trauma manifests as conditions like PTSD, depression, and anxiety
    • The importance of an intersectional perspective
    • Current treatments for mental health struggles stemming from racial trauma
    • Results from Dr. Williams’ research into psychedelic use amongst people of color
    • The importance of safe and supportive settings for psychedelic experiences
    • How shared life experiences between a therapist and client can strength the therapeutic alliance and improve outcomes
    • Why bias training is particularly important in the context of psychedelic therapy

    Quotes:

    “People of color who live in these white dominated Western contexts are continually bombarded by subtle —and not so subtle—messages about their worth, about their standing in society, about their intelligence, their character, on and on and on and on. And so really the daily onslaught just wears and wears away at people, and the stress of that can actually become traumatizing.” [1:49]

    “People heal from trauma when someone witnesses their pain, right? When people can compassionately witness your pain and join in it with you—this is the basis behind all therapeutic approaches for trauma treatment.” [10:13]

    “We saw [from our survey study] that many, many people of color are using psychedelics to manage racism, often very quietly. But it seems for many people to be quite effective and quite helpful.” [11:53]

    “We looked at some separate psychedelics where we had enough people who described a specific one like psilocybin or LSD or peyote in some cases. And so we were able to look at those psychedelics separately and we didn't actually find a difference. It didn't seem to matter which psychedelic it was. It seemed that they were all, more or less equally effective.” [15:20]

    Links:

    Dr. Williams’ website

    Dr. Williams on X

    Dr. Williams on Instagram

    Dr. Williams on LinkedIn

    Dr. Williams’ study “Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada”

    Behavioral Wellness Clinic - Connecticut

    Behavioural Wellness Clinic - Ottawa

    Masters Program in Psychedelics and Consciousness Studies at University of Ottawa

    Psychedelic Medicine Association

    Porangui

    続きを読む 一部表示
    35 分
  • Understanding Psychedelics and Neuroplasticity with Robin Carhart-Harris, PhD
    2025/06/12

    In this episode, Robin Carhart-Harris, PhD joins to elucidate the intersection of psychedelics and neuroplasticity. Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine’s ‘100 Next’ – a list of 100 rising stars shaping the future.

    Dr. Carhart-Harris begins by discussing the impact of psychedelics on neuroplasticity and mental health. He explains neuroplasticity as the brain's ability to change, emphasizing its role in mood disorders and substance use and describes how stress atrophies the brain, leading to mental illness. Dr. Carhart-Harris differentiates between neuroplasticity and neurogenesis, noting that while neurogenesis is limited in adults, neuroplasticity can be influenced by psychedelics like ketamine, psilocybin, and MDMA. In closing, he also discusses the entropic brain hypothesis, suggesting that increased brain entropy leads to richer subjective experiences.

    In this episode, you'll hear:

    • The relationship between neuroplasticity and “canalization”
    • Why homeostatic neuroplasticity may promote mental wellbeing
    • Differences between ketamine, MDMA, and serotonergic psychedelics in terms of neuroplasticity
    • The details of the entropic brain hypothesis
    • Psychedelics’ effect on the default mode network
    • The frontiers of research into psychedelics and neuroplasticity

    Quotes:

    “So changeability is what plasticity is. And neuroplasticity—that's the ability of the brain to change. Okay, and how is neuroplasticity related to mood disorders like depression and anxiety or substance use disorder or something like that? Well, that's a great question cause we don't have it entirely nailed down. But one of the most reliable findings in biological psychiatry is that stress atrophies the brain.” [2:47]

    “The main thing with ketamine is that the window of increased plasticity is brief… That makes sense because that reflects how ketamine seems to work therapeutically—that it provides relief somewhat short-term, unless it is twinned with, say, psychotherapy or you do repeat administration and get someone out of the rut they were in.” [22:15]

    “We’ve seen in people with depression, brain networks can become quite segregated from each other—they are ordinarily, they’re quite functionally separate and distinct—but that modularity might be a bit elevated in depression. But what we’ve seen with psilocybin therapy is that separateness between systems, that segregated quality of organization of brain networks, brain systems actually decreases after psilocybin therapy for depression. I’ll put it another way: the brain looks more globally interconnected after psilocybin therapy for depression and the magnitude of that… correlates with improvements.” [39:19]

    Links:

    Carhart-Harris Lab website

    Dr. Carhart-Harris on X

    Dr. Carhart-Harris’ 2025 article: “Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models”

    Dr. Carhart-Harris’ 2012 article: “Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin”

    Dr. Carhart-Harris’ 2010 article with Karl Friston: “The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas”

    Psychedelic Medicine Association

    Porangui

    続きを読む 一部表示
    45 分

Psychedelic Medicine Podcast with Dr. Lynn Marie Morskiに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。